Last reviewed · How we verify
Pompe disease — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Neogaa | AVALGLUCOSIDASE ALFA | Sanofi | Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] | 2021-01-01 | ||
| NEXVIAZYME | AVALGLUCOSIDASE ALFA-NGPT | GENZYME CORP | Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- GENZYME CORP · 1 drug in Pompe disease
- Sanofi · 1 drug in Pompe disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Pompe disease:
- Pompe disease treatment updates — RSS
- Pompe disease treatment updates — Atom
- Pompe disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Pompe disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pompe-disease. Accessed 2026-06-10.
Related
- Pompe disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing